LinkedIn

Do you know what's really funny? The fact that Depomed has posted for multiple positions on LinkedIn, and you have NO ONE currently with the company posting a 'like' for these slots. NO ONE.

 

How old are you? 12? Who cares? That’s just sad you need to move on

 

You care because you responded. Why don’t you go celebrate your updated severance package with my money Beatch Arthur!

We will move on when you and the rest of the criminals are behind bars.

 

Lol Keep dreaming princess

 

I will POS.

 

the “move on” guy still hasn’t moved on! why even comment if you are not glued to dep news like some rumour monitor?

 

Dear Poster,

Thanks for the heads up. I’ll be sure to like all posts on Linked In, and defend Depomed’s deception on severance pay.

Joe
“move on”

 

LMAO. Good luck in the job hunt after the move to Chicago and sale for $9/share.

 

What? Coll Aggreement is worth 7*135 = $12 / Share (diluted). Remaining business is worth $15 Share (diluted). Purdue Litigation is worth something $1-$4 (diluted, say $2). Debt is -6$. $12+$15+$2 - $6 = $23 Minimum. Growth not included.

 

but dear old Arthur made sure that he renegotiated his severance agreement by padding his payout from the pain force’s severance money to the tune of almost $4,000,000 total. Isn’t that some BS? I can’t wait to see you guys in court.

 

It was Gruenenthal, who decided to change to Coll, not Arthur. Depo failed to market Nucynta successfully. So, Change was needed and Gruenenthal was for Coll as they were successful in their marketing efforts. There was no other Choice for him to eliminate Sales Force.

 

FYI.... https://www.thepharmaletter.com/article/grunenthal-changes-partner-for-us-opioid-drug-marketing

 

Holy shit. This article is from MAY of 2017!!!! How come no one knew about this??????

 

That Article is from December 5, 2017. Apparently, Grünenthal was initiator of Change. Nontheless, Depo has US Patent rights until 2025 at least. The Agreement with Coll guarantees Depo a payment of 7x135m =945m Minimum. That is the sum, Depo paid for Nucynta to Jansen. This decision to eliminate Sales Force was not only in the head of A.H. People should see Big Picture before blaming him alone.

 

Maybe because you didn’t send out a written letter to the sales force acknowledging, addressing and responding as you were required to do.

 

"
Grünenthal changes partner for US opioid drug marketing

05-12-2017
German family-owned drugmaker Grünenthal has decided to end its partnership with US firm Depomed (Nasdaq: DEPO) for the marketing of its opioid pain management product Nucynta (tapentadol), saying that, in recent months, the US company has struggled to grow the drug.

Nucynta and Nucynta ER, for which Depomed acquired US right from Johnson & Johnson (NYSE: JNJ) in 2015 as part of a $1.05 billion deal, will instead by commercialized in the US territory by Collegium Pharmaceuticals (Nasdaq: COLL) from 2018 onwards. Collegium’s shares gained 9.2% to $18.50 in after-hours trading last night.

Last year, Depomed prevailed in a patent challenge on Nucynta from three generic drugmakers, which is expected to provide market exclusivity until December 2025 for Nucynta ER and Nucynta oral solution.

Grünenthal, the originator of tapentadol, said it has looked at various options to reinforce the performance of Nucynta, and strengthen its presence in the USA. But given the dynamics in the opioid market, Grünenthal concluded and agreed that transferring Nucynta to Collegium would be the best option.

Collegium is focused on pain management developing and commercializing next-generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.

"They are well-positioned in the market and successfully increased the sales of their opioid Xtampza [oxycodone extended-release capsules]in a very challenging and declining US-opioid market," said Gabriel Baertschi, chief executive, Grünenthal Group.

Nucynta is highly synergetic for Collegium. It is a perfect fit to more effectively compete on the market, and meet the needs of patients, physicians and payors. "We believe that adding Nucynta® to their portfolio will expand the continuum of care for pain patients and strengthen Collegium as a leader in pain management," Mr Baertschi stated.

Collegium is strongly incentivized to make Nucynta a success by paying a fixed royalty even for sales below a certain level (between $180 million and $243 million), and being rewarded if they exceed the upper range of the forecast ($258 million). Grünenthal will continue to receive a royalty rate based on certain net sales thresholds and will receive a fixed royalty income in the first four years, if the sales are above $180 million.

Upon closing of the deal, Collegium will pay an upfront license fee of $10.0 million, as well as a cash payment equal to Depomed’s cost of inventory with greater than 12 months dating at the time of close.

This agreement contributes to Grünenthal's financial strength and to some extent, removes the uncertainties linked to the US market development, while providing Grünenthal with a partner committed to pain management in the USA, the German firm stated."

 

and thanks for providing additional evidence on CHANGE IN CONTROL. Although, we really didn’t need it. The fact that you even used the argument was proof enough of deception. We got you on so many other thing anyway. Enjoy my additional 3 months of severance pay and the accelerated stock. You now will be paying 3x more.

 

O, what a tangled web we weave when first we practice to deceive! - Walter Scott

Would it have really been too easy and too honest to just do the right thing? Geesh. More company lies and cover-ups just exposed. This looks really bad, but my attorney loves it.

 

Let’s put this back on top of the feed for all the employees that were lied to about the real owner of Nucynta brand. US partnership was revoked and given to Collegium. Depomed you owe us our severance, stock, cobra, and all bonuses including the money you stole in 3rd quarter and regifted as SPIF money.

 

incredible